Adipose-derived stem cell therapeutics - American CryoStem Corporation

Drug Profile

Adipose-derived stem cell therapeutics - American CryoStem Corporation

Latest Information Update: 14 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator American CryoStem Corporation
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Cytokine stimulants; Growth stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 01 Nov 2014 Phase-I clinical trials in Multiple sclerosis in Cayman Islands (IV) (NCT02326935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top